Grade 2 Invasive Lobular Carcinoma Prognosis
Grade 2 invasive lobular carcinoma (ILC) has an intermediate prognosis with approximately 82% 5-year survival, though long-term outcomes depend critically on nodal status, lymphovascular invasion, and multifocality rather than grade alone 1.
Key Prognostic Factors
The prognosis for grade 2 ILC differs from invasive ductal carcinoma in important ways:
Tumor Grade Has Limited Prognostic Value in ILC
Unlike ductal carcinoma, tumor grade in ILC is not a strong independent predictor of survival 2. In young patients with node-negative ILC followed for 15 years, grade showed no association with distant recurrence-free survival (HR 1.40,95% CI 0.42-4.63) 2. The historical grading data showing 82% 5-year survival for grade 2 ILC comes from older studies 1, but more recent evidence suggests other factors matter more.
Critical Prognostic Factors That Actually Matter
Lymphovascular invasion (LVI) is a powerful predictor in ILC:
- Presence of LVI increases risk of distant recurrence nearly 3-fold (adjusted HR 2.81,95% CI 1.14-6.94) 2
Multifocality significantly worsens prognosis:
- Multifocal disease increases distant recurrence risk over 3-fold (adjusted HR 3.28,95% CI 1.49-7.22) 2
Nodal involvement has disproportionate impact in ILC compared to ductal carcinoma:
- While tumor size shows minimal prognostic impact in ILC, nodal status is particularly important 3
- Advanced nodal involvement carries especially high risk for breast cancer-specific mortality in ILC 3
Long-Term Outcomes
At 15-year follow-up, even low-risk luminal A-like ILC shows a trend toward worse survival compared to matched ductal carcinoma (15-year distant recurrence-free survival 63% in ILC vs. 74% in ductal carcinoma, HR 1.50,95% CI 0.98-2.29) 2. This suggests ILC may have more indolent but persistent recurrence patterns over time.
Treatment Implications for Grade 2 ILC
Based on current guidelines 4, 5:
For node-negative disease:
- Genomic testing (OncotypeDX or equivalent) should guide chemotherapy decisions, not grade alone
- Low genomic scores (≤12) support endocrine therapy alone in postmenopausal women
- In premenopausal women, consider ovarian function suppression (OFS) even with low-intermediate scores
For node-positive disease:
- Chemotherapy decisions become more complex with ILC given lower pathologic complete response rates 4
- For stage 3, low-grade, strongly ER-positive lobular cancer with limited nodal involvement, there is "limited enthusiasm" for chemotherapy given low genomic risk likelihood 4
- However, nodal involvement in ILC carries particularly poor prognosis and may warrant more aggressive systemic therapy 3
Common Pitfalls
- Do not rely on grade alone to make treatment decisions in ILC—assess LVI, multifocality, and nodal status carefully
- Do not assume tumor size predicts outcome as it does in ductal carcinoma; a larger ILC with negative nodes may have better prognosis than a smaller node-positive tumor 3
- Do not undertreated node-positive ILC based on favorable grade or hormone receptor status—nodal involvement is particularly ominous in this histology 3